Administration of more than 400 mg/day of sorafenib for 1 month prolonged progression-free survival (PFS) in Japanese patients with advanced renal cell carcinoma (RCC).
This indicated that it is very important to prevent and manage side effects of sorafenib avoiding drug withdrawal or dose reduction. I mention the side effects of sorafenib and countermeasures in this review.
Written by:
Nakayama M, Arai Y, Nishimura K. Are you the author?
The Department of Urology, Osaka Medial Center for Cancer and Cardiovascular Diseases.
Reference: Hinyokika Kiyo. 2012 Nov;58(11):635-7.
PubMed Abstract
PMID: 23254792
Article in Japanese.
UroToday.com Renal Cancer Section
